ABEONA THERAPEUTICS INC.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Securities Trading Arrangements of Directors and Executive Officers
During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act (a “Rule 10b5-1 trading arrangement”) or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K), except as disclosed below.
On August 14, 2026, Vishwas Seshadri, the Company’s Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 360,000 shares of our common stock. The duration of the arrangement is until May 14, 2028, or the date on which the transactions under the arrangement are completed.
On August 17, 2026, Madhav Vasanthavada, the Company’s Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 60,000 shares of our common stock. The duration of the arrangement is until November 12, 2027, or the date on which the transactions under the arrangement are completed.
On August 18, 2026, Brendan O’Malley, the Company’s Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 100,000 shares of our common stock. The duration of the arrangement is until August 17, 2027, or the date on which the transactions under the arrangement are completed.
On August 18, 2026, Donald Wuchterl, a member of the Company’sboard of directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 65,000 shares of our common stock. The duration of the arrangement is until November 22, 2027, or the date on which the transactions under the arrangement are completed.
On August 18, 2026, Leila Alland, M.D., a member of the Company’sboard of directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 69,996 shares of our common stock. The duration of the arrangement is until May 16, 2027, or the date on which the transactions under the arrangement are completed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.